Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_assertion type Assertion NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_head.
- NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_assertion wasGeneratedBy ECO_0000203 NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_provenance.
- NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_assertion wasDerivedFrom befree-20150227 NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_provenance.
- NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_assertion SIO_000772 21761433 NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_provenance.
- NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_assertion evidence source_evidence_literature NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_provenance.
- NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_provenance.